Name: Q&A: Poolbeg Pharma’s Jeremy Skillington on AI-led RSV breakthrough
Uploaded: 2023-12-20T07:46:47.716811+00:00
Duration: 388 s
Channel: Vox Markets

Vox Markets

Jeremy Skillington, CEO of Poolbeg Pharma, talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates

00:28 Details of the latest results of lab-based analysis of RSV drug candidates.
01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery.
2:41 The importance of the data quality offered by human challenge models in lab-base analysis.
4:35 The growing importance of AI in drug discovery, and how Poolbeg’s leading position should open up partnering opportunities with biopharma groups.

Jeremy Skillington, CEO of Poolbeg Pharma, talks Vox Markets through the latest positive results of its lab-based, AI led analysis of its RSV drug candidates00:28 Details of the latest results of lab-based analysis of RSV drug candidates. 01:24 How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery. 2:41 The importance of the data quality offered by human challenge models in lab-base analysis. 4:35 The growing importance of AI in drug discovery, and how Poolbeg’s leading position should open up partnering opportunities with biopharma groups.

Details of the latest results of lab-based analysis of RSV drug candidates.

How this type of drug discovery offers cost and risk advantages over traditional forms of drug discovery.

The importance of the data quality offered by human challenge models in lab-base analysis.

The growing importance of AI in drug discovery, and how Poolbeg’s leading position should open up partnering opportunities with biopharma groups.

https://d3ev5earl6dvd0.cloudfront.net/public-media/videos/006/788/006788/video_Hjs2nMZ.mp4